State Board of Administration of Florida Retirement System Boosts Stock Position in Catalent, Inc. (NYSE:CTLT)

State Board of Administration of Florida Retirement System boosted its holdings in Catalent, Inc. (NYSE:CTLT) by 0.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 189,038 shares of the company’s stock after purchasing an additional 328 shares during the period. State Board of Administration of Florida Retirement System’s holdings in Catalent were worth $10,671,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of CTLT. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in shares of Catalent by 2,792.9% during the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 516,390 shares of the company’s stock valued at $29,150,000 after buying an additional 498,540 shares during the last quarter. ProShare Advisors LLC lifted its position in shares of Catalent by 15.3% during the 1st quarter. ProShare Advisors LLC now owns 28,763 shares of the company’s stock valued at $1,624,000 after buying an additional 3,814 shares during the last quarter. Russell Investments Group Ltd. lifted its position in shares of Catalent by 14.9% during the 1st quarter. Russell Investments Group Ltd. now owns 27,636 shares of the company’s stock valued at $1,560,000 after buying an additional 3,578 shares during the last quarter. Headlands Technologies LLC lifted its position in shares of Catalent by 101.3% during the 1st quarter. Headlands Technologies LLC now owns 2,855 shares of the company’s stock valued at $161,000 after buying an additional 1,437 shares during the last quarter. Finally, Forsta AP Fonden purchased a new position in shares of Catalent during the 1st quarter valued at $2,128,000.

Catalent Price Performance

Shares of NYSE CTLT opened at $57.91 on Friday. The firm has a market capitalization of $10.48 billion, a P/E ratio of -9.49, a P/E/G ratio of 2.39 and a beta of 1.16. The company has a quick ratio of 1.77, a current ratio of 2.51 and a debt-to-equity ratio of 1.37. The stock’s 50-day simple moving average is $55.92 and its two-hundred day simple moving average is $55.21. Catalent, Inc. has a twelve month low of $31.80 and a twelve month high of $60.20.

Catalent (NYSE:CTLT) last announced its earnings results on Wednesday, May 8th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.36). The business had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.11 billion. Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. As a group, equities analysts anticipate that Catalent, Inc. will post -0.17 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on CTLT. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $63.50 price target on shares of Catalent in a research report on Thursday, July 11th. Stephens reaffirmed an “equal weight” rating and set a $63.50 price target on shares of Catalent in a research report on Thursday, April 4th. StockNews.com assumed coverage on Catalent in a research note on Tuesday. They set a “sell” rating on the stock. Finally, Barclays boosted their price objective on Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research note on Friday, June 28th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $55.65.

Insiders Place Their Bets

In other Catalent news, insider Ricky Hopson sold 1,401 shares of the company’s stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total value of $76,018.26. Following the transaction, the insider now directly owns 20,617 shares in the company, valued at approximately $1,118,678.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Ricky Hopson sold 1,401 shares of the stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total transaction of $76,018.26. Following the transaction, the insider now directly owns 20,617 shares in the company, valued at approximately $1,118,678.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Matti Masanovich sold 2,993 shares of the stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $56.74, for a total value of $169,822.82. Following the transaction, the chief financial officer now owns 33,871 shares in the company, valued at $1,921,840.54. The disclosure for this sale can be found here. Corporate insiders own 0.31% of the company’s stock.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.